# Memorial Sloan Kettering Cancer Center: Phase 2 study closed enrollment, 59 enrolled (Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL))

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Sponsor type | Academic and hospital |
| Study | Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
| NCT ID | NCT02570542 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Diffuse Large B-cell Lymphoma (DLBCL); Relapsed Diffuse Large B-cell Lymphoma (DLBCL); Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
| Intervention types | procedure, drug |
| Target enrollment | 59 |
| Site countries | United States |
| Posted | 2015-10-07 |
| Planned start | 2015-10 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-30 |
| Last update posted | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT02570542). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.